

Status: Currently Official on 16-Feb-2025

Official Date: Official as of 01-Aug-2017

Document Type: USP Monographs

DocId: GUID-39FF6DB4-9AD6-4C6D-8AF7-18C577B683BA\_1\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M55930\\_01\\_01](https://doi.org/10.31003/USPNF_M55930_01_01)

DOI Ref: n28ze

© 2025 USPC

Do not distribute

# Neomycin Sulfate and Dexamethasone Sodium Phosphate Ophthalmic Ointment

## DEFINITION

Neomycin Sulfate and Dexamethasone Sodium Phosphate Ophthalmic Ointment is a sterile ointment containing Neomycin Sulfate and Dexamethasone Sodium Phosphate. It contains the equivalent of NLT 90.0% and NMT 135.0% of the labeled amount of neomycin, and the equivalent of NLT 90.0% and NMT 110.0% of the labeled amount of dexamethasone phosphate ( $C_{22}H_{30}FO_8P$ ).

[NOTE—Where Neomycin Sulfate and Dexamethasone Sodium Phosphate Ophthalmic Ointment is prescribed without reference to the quantity of neomycin or dexamethasone phosphate contained therein, a product containing 3.5 mg of neomycin and 0.5 mg of dexamethasone phosphate per g shall be dispensed.]

## IDENTIFICATION

- **A. THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201BNP):** Meets the requirements
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for *Dexamethasone Phosphate*.

## ASSAY

### • NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a weighed portion of Ophthalmic Ointment in a separator with about 50 mL of [ether](#), and extract with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.3* to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

**Acceptance criteria:** 90.0%–135.0%

### • DEXAMETHASONE PHOSPHATE

**Buffer:** 6.9 g/L of [monobasic sodium phosphate](#)

**Mobile phase:** [Methanol](#) and *Buffer* (52:48)

**Diluent:** Dissolve 0.29 g of [dibasic sodium phosphate](#) in 450 mL of [water](#), and add 550 mL of [alcohol](#).

**Standard solution:** 33 µg/mL of [USP Dexamethasone Sodium Phosphate RS](#) in *Diluent*. Prepare this solution freshly.

**Sample solution:** Nominally 30 µg/mL of dexamethasone phosphate, prepared as follows. Transfer a portion of Ophthalmic Ointment containing nominally 3 mg of dexamethasone phosphate to a suitable beaker. Add 65 mL of *Diluent*, and heat just to boiling. Pour the contents of the beaker into a separator containing 45 mL of isooctane. After shaking for 1 min, decant the lower layer into a 100-mL volumetric flask. Rinse the beaker with two 15-mL portions of *Diluent*, extracting the remaining [isooctane](#) in the separator with each portion, and decanting the lower layer from each extraction into the 100-mL volumetric flask. Dilute with *Diluent* to volume, and mix. Pass through a suitable filter.

## Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 3.9-mm × 30-cm; 10-µm packing L1

**Flow rate:** 1.5 mL/min

**Injection volume:** 20 µL

## System suitability

**Sample:** *Standard solution*

[NOTE—The retention time for dexamethasone phosphate is about 8.5 min.]

## Suitability requirements

**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of the labeled amount of dexamethasone phosphate ( $C_{22}H_{30}FO_8P$ ) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (M_{r1}/M_{r2}) \times 100$$

 $r_u$  = peak response from the *Sample solution* $r_s$  = peak response from the *Standard solution* $C_s$  = concentration of [USP Dexamethasone Sodium Phosphate RS](#) in the *Standard solution* ( $\mu\text{g/mL}$ ) $C_u$  = nominal concentration of dexamethasone phosphate in the *Sample solution* ( $\mu\text{g/mL}$ ) $M_{r1}$  = molecular weight of dexamethasone phosphate, 472.44 $M_{r2}$  = molecular weight of dexamethasone sodium phosphate, 516.40**Acceptance criteria:** 90.0%–110.0%**SPECIFIC TESTS**

- [STERILITY TESTS \(71\)](#): Meets the requirements
- **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\), Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Dexamethasone Sodium Phosphate RS](#)[USP Neomycin Sulfate RS](#)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE OPHTHALMIC OINTMENT	<a href="#">Julie Zhang</a> Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	BIO42020 Biologics Monographs 4 - Antibiotics

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 40(6)

**Current DocID: GUID-39FF6DB4-9AD6-4C6D-8AF7-18C577B683BA\_1\_en-US****DOI:** [https://doi.org/10.31003/USPNF\\_M55930\\_01\\_01](https://doi.org/10.31003/USPNF_M55930_01_01)**DOI ref:** [n28ze](#)